

Rhythm Betters ColoSTAT® Results

- Further testing refines ColoSTAT® blood test for cancer detection
- Inclusion of Lifestyle Risk Factors as part of the proprietary algorithm can increase cancer detection performance

6 May 2021, Melbourne: Rhythm Biosciences (ASX: RHY) is pleased to confirm that ongoing enhancements to the proprietary algorithm underpinning the ColoSTAT® technology, has demonstrated a potential to further increase accuracy, through the inclusion of known lifestyle factors data.

Background

A number of Lifestyle Related Factors (LRF) have been linked to the incidence risk of colorectal cancer. Diet, weight, exercise, smoking, and type 2 diabetes are some of the strongest factors that can contribute to the onset of colorectal cancer.

Rhythm recently announced excellent results in its Study 6 findings (ASX Announcement 16 March 2021), which showed that the ColoSTAT® test-kit performed with an accuracy (Sensitivity¹) of 84% (at 95% Specificity²). This landmark announcement showed that Rhythm's ColoSTAT® simple blood test outperformed the current market standard faecal test.

ColoSTAT® Algorithm Enhancement

The artificial intelligence framework behind Rhythm's proprietary algorithm technology has the capability to continue to learn as the database grows with new information. This means the technology has the potential to deliver even further performance improvements.

The Company can confirm a promising enhancement with the addition of LRF that has shown to increase colorectal cancer detection performance. Preliminary testing³ with the addition of LRF, has demonstrated an **increased accuracy (Sensitivity¹) of the ColoSTAT® test by 5%.**

Table 1 - ColoSTAT® Performance Comparison - Study 6 vs LRF Enhancement

	Specificity ²	Sensitivity ¹
ColoSTAT® - Study 6 (16 March 2021)	95%	84%
ColoSTAT® - Study 6 + LRF Enhancement (5 May 2021)	95%	88%

The potential of the LRF enhancement will be further developed and tested on a larger number of samples where a decision will be made for its availability in the final ColoSTAT® test-kit.

Rhythm CEO, Glenn Gilbert, commented:

"We have shown that ColoSTAT® is already superior in detecting colorectal cancer when compared to the current market standard faecal test.

The capability to broaden the effectiveness of our core cancer detection technology, via a simple addition of commonly measured data, is extremely exciting in the context of our objective to reduce the social and economic burden of colorectal cancer globally."

With authority by the Board.

For further information, please contact:

Glenn Gilbert
Chief Executive Officer
+61 3 8256 2880

¹ **Sensitivity** is the ability of the test to correctly identify those patients with colorectal cancer, that is, the percentage of people with colorectal cancer who are correctly identified as having illness.

² **Specificity** is the ability of the test to correctly identify people who do not have colorectal cancer, that is, the percentage of people without colorectal cancer who are correctly identified as not having cancer.

³ **LRF enhancement study** was conducted on 100 Study 6 samples (N=100) comprising of 50 cancerous and 50 healthy samples.

About Rhythm Biosciences

Rhythm Biosciences (ASX: RHY) is a transformative, predictive diagnostics company, specialising in early cancer detection. Rhythm's initial business pursuit is centred upon technology originally developed by the CSIRO and involves the development and commercialisation of a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT[®] also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT[®] is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure. ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer via increasing current screening rates.

Globally, over 850,000 people die from colorectal cancer each year. Colorectal cancer is typically diagnosed at a later stage when there is a poor prognosis for long-term survival. Annual estimated unscreened 50-74-year old's is estimated at +130m for the US, EU and AU alone, with this market potential being more than \$6.5b.